文献速递瘢痕与激光烧伤创面修复

A型肉毒毒素联合曲安奈德通过调节表皮神经过度支配缓解瘢痕瘙痒

Synergic Effect of Botulinum Toxin Type A and Triamcinolone Alleviates Scar Pruritus by Modulating Epidermal Hyperinnervation: A Preliminary Report.
PubMed 文献 · Aesthet Surg J · 2021-01-01

临床研究将每例患者瘢痕分为两半,分别接受TAC/BTX-A联合治疗与单用TAC,每4周一次共3次,末次治疗后4周联合组瘙痒VAS改善显著优于单用TAC(P=0.04)。大鼠烧伤模型显示联合治疗可减轻烧伤后瘙痒并降低表皮内神经纤维密度、下调NGF与TRPV1表达。

要点

  • 瘢痕内注射TAC联合BTX-A较单用TAC更能持续缓解瘢痕瘙痒。
  • 联合治疗可能通过降低表皮内神经纤维密度和下调NGF、TRPV1发挥作用。
  • 动物模型支持联合方案对烧伤后瘙痒的改善,但样本量有限需进一步验证。

核心结论

  • TAC/BTX-A联合治疗在缓解瘢痕瘙痒方面显示出增强且持久的临床疗效,可能通过调节表皮神经支配和TRPV1表达实现。

研究设计与样本

  • 临床研究为自身对照设计,每例患者瘢痕分为两半分别接受TAC/BTX-A与单用TAC,每4周一次共3次。
  • 动物实验将大鼠分为对照、未治疗烧伤、TAC、BTX-A和TAC/BTX-A共5组。

主要发现

  • 临床研究中,TAC/BTX-A在末次治疗后4周(V4)较单用TAC显著降低瘢痕瘙痒(P=0.04)。
  • 大鼠烧伤后4周,TAC、BTX-A及TAC/BTX-A均减轻瘙痒(P=0.03、P=0.0054、P=0.0053)。
  • TAC/BTX-A较未治疗烧伤显著降低表皮内神经纤维密度(P=0.0008)。
  • TAC/BTX-A下调神经生长因子和瞬时受体电位香草酸亚型1的表达。

临床怎么用

  • 对伴有瘙痒的瘢痕患者,可考虑TAC联合BTX-A注射以增强止痒效果并延长疗效。

局限性

  • 本文为初步报告,临床研究为自身对照设计且样本量未报告,动物模型结果需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients often experience scar-related pruritus, which adversely affects quality of life. Triamcinolone acetonide (TAC) is widely used to treat pathologic scars, and botulinum toxin type A (BTX-A) reportedly improves scarring and associated discomfort. OBJECTIVES: The aim of this study was to investigate the clinical efficacy of combining TAC and BTX-A to reduce scar itch; potential mechanisms were investigated via an animal model. METHODS: For the clinical study, each scar on a patient was divided into 2 equal parts, with one part receiving TAC/BTX-A and the other TAC alone. Therapeutic interventions were administered over 3 sessions at 4-week intervals. Itch intensity was measured on a visual analog scale before each therapeutic intervention (V1, V2, V3) and 4 weeks after the last intervention (V4). For the animal model, rats were allocated into 5 groups: control, untreated burn, TAC, BTX-A, and TAC/BTX-A. We evaluated alloknesis in the right hind paw and analyzed possible molecular mechanisms. RESULTS: In humans, TAC/BTX-A significantly reduced scar itch compared with TAC alone at V4 (P = 0.04). In rats, post-burn itch was mitigated at 4 weeks after treatment with TAC, BTX-A, and TAC/BTX-A (P = 0.03, P = 0.0054, and P = 0.0053, respectively). TAC/BTX-A significantly decreased the density of intraepidermal nerve fibers post-burn relative to the untreated burn (P = 0.0008). TAC/BTX-A downregulated the expressions of nerve growth factor and protein transient receptor potential vanilloid subtype 1. CONCLUSIONS: TAC/BTX-A therapy exhibited enhanced and sustained clinical efficacy in relieving scar itch, possibly via modulating epidermal innervation and expression of transient receptor potential vanilloid subtype 1 .

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Huang SH, Wu KW, Lo JJ, et al. Synergic Effect of Botulinum Toxin Type A and Triamcinolone Alleviates Scar Pruritus by Modulating Epidermal Hyperinnervation: A Preliminary Report. Aesthet Surg J. 2021. PMID: 33662123. doi:10.1093/asj/sjab105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。